Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032280 | 0.80 | EGLN2 (0.37) | PDE4AEIF4EEGLN2SCN9AS1PR1 | |
| SCHEMBL2034990 | 0.78 | CYP1A1 (0.41) | EIF4E | |
| SCHEMBL2035404 | 0.73 | CYP17A1 (0.43) | — | |
| SCHEMBL2052330 | 0.72 | ALDH1A1 (0.42) | PDE4AEIF4EEGLN2 | |
| SCHEMBL2032490 | 0.71 | ESR1 (0.42) | EIF4EEGLN2CYP11B1CYP11B2SLC22A12 | |
| SCHEMBL2154193 | 0.70 | CYP11B2 (0.53) | EGLN2CYP11B1CYP11B2SLC22A12 | |
| SCHEMBL6514538 | 0.68 | HRH2 (0.41) | EIF4EEGLN2CYP11B1CYP11B2SLC22A12 | |
| SCHEMBL15331313 | 0.68 | CYP2A6 (0.31) | — | |
| SCHEMBL2033018 | 0.67 | PTGS1 (0.38) | EIF4ECYP11B2 | |
| SCHEMBL152218 | 0.67 | ALDH1A1 (0.46) | EGLN2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859611-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2512247-B1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586624-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2512247-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011075478-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | PDE4A 1648/4885EIF4E 4655/4885EGLN2 2496/4885 |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | PDE4A 1648/4885EIF4E 4655/4885EGLN2 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.